Definitive Contract 75N91021C00047
Award Date
9/16/21
Potential Completion Date
3/15/26
Potential Value
$2M
Federal Agency
National Cancer Institute
Awardee
Kephera Diagnostics LLC
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Framingham, MA 01702, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The $299,997.00 contract was awarded to Kephera Diagnostics LLC, a for-profit limited liability company, to develop screening and point-of-care diagnostic assays for the liver fluke infections Opisthorchis viverrini and Clonorchis sinensis. This SBIR contract, which was set...
This is a $300,000.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Kephera Diagnostics LLC, a for-profit limited liability company. The contract is part of the SBIR 133 program, which does not have a set-aside designation. The contract focuses on advancing Kephera Diagnostics' research and development of innovative diagnostic solutions for infectious diseases, with a particular emphasis on neglected tropical...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a $300,000 Firm Fixed Price Definitive Contract to Kephera Diagnostics LLC, a for-profit limited liability company, for the NOVEL DIAGNOSTIC BIOMARKERS DISCOVERY AND VALIDATION FOR MALARIA AND SELECT NEGLECTED TROPICAL DISEASES SBIR PHASE I project. This Small Business Innovation Research (SBIR) Phase I contract is set aside for small businesses and has an ultimate completion date of November 30,...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Kephera Diagnostics LLC, a for-profit limited liability company, to develop a biomarker-based test of cure (TOC) to evaluate treatment outcome during the chronic phase of Chagas infection. The contract, a Definitive Contract with Firm Fixed Price pricing, has a potential value of $300,000.00 and...
This is a $300,000.00 firm fixed price contract awarded by the National Institutes of Health (NIH), part of the Department of Health and Human Services, to Nanohmics Inc., a small business, under the Small Business Innovation Research (SBIR) program. The contract is for the development of DNA aptamer-based lateral flow assays for detecting liver flukes in Phase I of the SBIR program. The contract has a completion date of December 15, 2021 and was awarded on September 16, 2019. Nanohmics Inc....
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract for $299,991.00 to Qoolabs Inc., a self-certified small disadvantaged business. The contract is for the development of point-of-care diagnostics for the detection of the liver flukes Opisthorchis viverrini and Clonorchis sinensis, under Topic 388. The work will be performed by Qoolabs Inc. in San Diego, California. Qoolabs...
This is a $1,994,911 firm fixed price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Earlydiagnostics Inc., doing business as Earlydx. The contract is part of the NCI's Small Business Innovation Research (SBIR) program and has a total small business set-aside designation. The contract supports Earlydx's research and development of a cloud-based liquid-biopsy platform for the Cancer Research Data Commons. Earlydx is a...
<p>This is a $299,961.00 SBIR Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Cubit Diagnostics, Inc. (doing business as Arete Biosciences) for the development of an ultrasensitive, rapid, and easy-to-use at-home molecular test for Hepatitis C, Hepatitis B, and HIV. The contract has a firm fixed price and a completion date of April 30, 2025. It is designated as a Total Small Business set-aside contract.</p>
This $299,889 firm fixed price definitive contract was awarded by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to Esper Biosciences Inc. for hepatitis C diagnostics using nanopore field-effect sensors. The contract is being performed in Ithaca, NY from September 2021 through September 2023. It falls under a Small Business Innovation Research solicitation issued by the NIH and Centers for Disease Control and Prevention seeking proposals for...
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>